No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
PYC Therapeutics Advances Key Drug Programs
PYC Therapeutics Completes Initial Dosing for Retinitis Pigmentosa Study
PYC Therapeutics Begins Multiple Dose Trial for Blinding Eye Disease Drug
PYC Therapeutics Advances Trial for Drug Candidate; Shares Up 4%
Canaccord Genuity Starts PYC Therapeutics at Buy With AU$0.22 Price Target
Why IDP Education, Novonix, PYC, and Regis Resources Share Are Racing Higher
No Data